Pfizer’s Nyvepria (pegfilgrastim-apgf) 6mg pre-filled syringe formulation has been approved by the US Food and Drug Administration but will remain off the market for now, as the company continues to grapple with Amgen over intellectual property shielding its Neulasta (pegfilgrastim) reference product.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?